Rodent feces, roach, spoiled food: Worst Triangle restaurant inspections in June
Sanitation scores and their corresponding letter grades are used in North Carolina to assess restaurants' adherence to rules and standards intended to mitigate and prevent the spread of food-borne illnesses.
Here are the restaurants that received some of the lowest ratings around the area.
Luna Azul Tacos & Mariscos Restaurant at 2645 E Millbrook Rd. in Raleigh
The restaurant received a score of 88% during an inspection on Wednesday, June 4 and was in violation of 20 standards.
Violations included several foods in cold-hold units that spoiled and were moldy, like rice, chicken, jalapenos, cut avocado, banana leaves, beans, corn silk for liver and beef. There was also residue accumulation and dead fruit flies in reach-in cold-hold units, along with an open bag of sugar and boxes of tortillas stored on the floor.
The restaurant previously scored 96.5% in November 2024.
It has not been reinspected, according to county documents, as of publication.
Raleigh Beer Garden at 614 Glenwood Ave Suite B in Raleigh
The restaurant received a score of 87.5% during an inspection on Tuesday, June 10 and was in violation of 12 standards.
Violations included a small live baby rodent observed in the kitchen and a live roach observed along the walls in the kitchen, a tomato slicer seen with food debris and rodent feces and cleaning needed of all shelving throughout the kitchen due to food debris and rodent feces.
The restaurant previously scored 96% in January 2025 and 97.5% in June 2024.
It has not been reinspected, according to county documents, as of publication.
Naga's South Indian Cuisine at 1000 Lower Shiloh Way in Morrisville
The restaurant received a score of 84% during an inspection on Tuesday, June 24 and was in violation of 18 standards.
Violations included raw shrimp stored directly above ready-to-eat sauce, a dead mouse seen on the floor in the middle of the dry storage room and containers of food were stored on the floor throughout the kitchen, within the walk-in cooler, and within the walk-in freezer.
The restaurant previously scored 93% in January 2025 and 88% in December 2024.
It has not been reinspected, according to county documents, as of publication.
Mi Cancun #3 at 1400 Boulderstone Way in Cary
The restaurant received a score of 86.5% on Thursday, June 26 and was in violation of 10 standards.
Violations included raw shell eggs stored above lettuce, cheese and other ready-to-eat foods in the walk-in cooler, a few flies present in the kitchen and seen landing on exposed foods and multiple foods in multiple coolers observed well above necessary temperatures.
The restaurant previously scored 94% in January 2025 and 95% in October 2024.
It has not been reinspected, according to county documents, as of publication.
Note: The Wake County inspection management system lists this establishment as Mi Cancun #3 but the restaurant's website lists it as Mi Cancun Cary.
Asian Kitchen at 1125 NC-54 in Durham
The restaurant received a score of 87.5% during an inspection on Monday, June 2 and was in violation of 18 standards.
Violations included cooked pork stored near uncooked pork and beef in a freezer, employees using bare hands when switching between raw and cooked food products and cooked food stacked high at room temperature in the make line.
The restaurant previously scored 97% in January 2025.
It was reinspected on Tuesday, June 10 and scored 88%.
The House Restaurant & Catering at 4310 S. Miami Blvd. in Durham
The restaurant received a score of 84.5% on Monday, June 2 and was in violation of 23 standards.
Violations included foods not being frozen in the walk-in freezer, some foods in the warmer and pancake mix, maseca, minced garlic and bags of bread crumbs on a storage rack were left uncovered while not in use. An employee also handled ready-to-eat food with bare hands.
The restaurant previously scored 93.5% in February 2025 and 91% in October 2024.
It has not been reinspected, according to county documents, as of publication.
Thai 55 at 2223 N.C. 54, Suite Q in Durham
The restaurant received a score of 89.5% during an inspection on Wednesday, June 4 and was in violation of 12 standards.
Violations included raw shell eggs stored above dressing and sauces inside the low reach-in cooler next to the grill area, wrapped portions of cooked noodles sitting at room temperature on the counter and multiple items in the reach-in and walk-in cooler observed without dates.
The restaurant previously scored 91.5% in February 2025 and 96.5% in July 2024.
It has not been reinspected, according to county documents, as of publication.
Mi Barrio at 5023 Wake Forest Hwy in Durham
The restaurant received a score of 86% on Thursday, June 26 and was in violation of 14 standards.
Violations included raw bacon in the same container as a package of cooked ham, cups stacked wet and cleaning needed of stove and oven area as well as inside of shelving in the dining area.
The restaurant previously scored 91% in January 2025 and 90% in May 2024.
It has not been reinspected, according to county documents, as of publication.
All restaurants inspected in Orange, Johnston and Chatham counties in June received A grades.
Have a question about your community you'd like answered? Or maybe a tip or story idea you'd like to share? The service journalism teams at The News & Observer and The Charlotte Observer want to hear from you.
If you have a question about the Charlotte area, send The Charlotte Observer team a question by submitting questions to this form.
If you have a question about Raleigh or a Triangle area community, send The News & Observer team a question by submitting questions to this form.
Where was Netflix's 'The Waterfront' filmed? Here's a list of NC locations
The best cocktail bar in the Triangle has a drink menu as vibrant as the decor
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
32,000 pounds of meat products recalled due to false USDA inspection marks
A New Jersey-based company, Sabrositos Hondurenos, LLC, is recalling about 32,000 pounds of various meat products with a false USDA mark of inspection, meaning the meats didn't go through proper federal examination, according to federal officials. In an alert shared Thursday, the U.S. Department of Agriculture's Food Safety and Inspection Service said the recalled products are falsely labeled with establishment number "EST. 1785," which "does not exist," they said. The items, which include chorizo (sausage), pork chops and ribs, were shipped to retail locations and restaurants nationwide and were produced with various dates before Aug. 20, 2025. The recall includes the following: Homestyle chorizo labeled "OLANCHO Chorizo Suelto Olanchano SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked pork chops labeled "OLANCHO Chuleta Ahumada Olanchana SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked chorizo labeled "OLANCHO Chorizo Ahumado Olanchano SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Cased homestyle chorizo labeled "OLANCHO Chorizo Olanchano Criollo SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked BBQ spicy chorizo labeled "OLANCHO Chorizo Parrillero SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages)Smoked ribs labeled "OLANCHO Costilla Ahumada Olanchana SABROCITOS HONDUREÑOS" (14-oz. vacuum-sealed packages) As more information becomes available, FSIS said it may add more items to the recalled product list, so consumers should keep an eye on the website for updates. So far, there have been no confirmed reports of adverse reactions due to these products, but the USDA says they should be considered "misbranded and unsafe to eat." Anyone concerned about a reaction should contact a healthcare provider, the agency added. Consumers can contact Diego Funez Garrido, owner of Sabrositos Hondurenos, LLC at 908-274-4206 for any questions regarding the recall, the alert added. Trump sounds off on potential security guarantees for Ukraine Man advocates for school zone and driver safety after personal tragedy What to know about the Menendez brothers' parole hearings Solve the daily Crossword


CBS News
3 hours ago
- CBS News
32,000 pounds of meat products recalled due to false USDA inspection marks
Sabrositos Hondurenos, LLC is recalling about 32,000 pounds of various meat products with a false USDA mark of inspection, meaning the meats didn't go through proper federal examination, according to federal officials. In an alert shared Thursday, the U.S. Department of Agriculture's Food Safety and Inspection Service said the recalled products are falsely labeled with establishment number "EST. 1785," which "does not exist," they said. The items, which include chorizo (sausage), pork chops and ribs, were shipped to retail locations and restaurants nationwide and were produced with various dates before Aug. 20, 2025. The recall includes the following: As more information becomes available, FSIS said it may add more items to the recalled product list, so consumers should keep an eye on the website for updates. So far, there have been no confirmed reports of adverse reactions due to these products, but the USDA says they should be considered "misbranded and unsafe to eat." Anyone concerned about a reaction should contact a healthcare provider, the agency added. Consumers can contact Diego Funez Garrido, owner of Sabrositos Hondurenos, LLC at 908-274-4206 for any questions regarding the recall, the alert added.
Yahoo
6 hours ago
- Yahoo
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET DURHAM, N.C., and BEIJING, Aug. 21, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the six-month period ended June 30, 2025. In the first half of 2025, Brii Bio rapidly advanced its core hepatitis B virus (HBV) functional cure program through multiple confirmatory Phase 2b trials, including ENRICH and ENHANCE studies, seeking combination regimens with higher HBV functional cure rates. Encouraged by promising data from Cohort 4 of the ENSURE study, presented at both the Asian Pacific Association for the Study of the Liver (APASL) and the European Association for the Study of the Liver (EASL) Congress 2025 supporting the potential of its patient enrichment strategy through BRII-179 induced anti-HBs response, the Company initiated a new cohort in an amended protocol within the ENHANCE study. This amendment evaluates a new triple regimen cohort with BRII-179 and elebsiran combination treatment followed by an added short-course pegylated interferon alpha (PEG-IFNα) treatment. This new cohort was fully enrolled in July 2025. Beyond its HBV pipeline, Brii Bio entered into a strategic license collaboration with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group") for the development of soralimixin (BRII-693) in the Greater China region. The Company has expanded its new discovery efforts to further broaden its portfolio and will continue to pursue partnership to extend the cash runway. With effective cost control measures in place, Brii Bio remains well-capitalized, maintaining a cash position of US$289.9 million, which is sufficient to support its late-stage development plans for its core HBV functional cure program and early discovery initiatives. "We made significant strides in our HBV cure program during the first half of 2025, highlighted by encouraging data from Cohort 4 of the ENSURE study and the rapid advancement of ENRICH and ENHANCE studies." said Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, "These achievements reflect Brii's experience and commitment to discovering innovative curative treatments for patients with chronic HBV infection. Meanwhile, the out-licensing of soralimixin in Greater China and our continued investment in early-stage discovery programs reinforce our strategy of combining internal innovation with strategic external collaborations to drive sustainable growth." Corporate and Clinical Updates HBV Program Brii Bio continues to advance its HBV pipeline with a strong focus on achieving higher rates of HBV functional cure through novel combination regimens. The Company is progressing multiple ongoing Phase 2b combination studies (ENSURE, ENRICH and ENHANCE) with its differentiated HBV candidates, including elebsiran, an HBV-targeting siRNA, and BRII-179, a recombinant protein-based HBV immunotherapeutic. BRII-179 demonstrated encouraging results in the Cohort 4 of ENSURE study, with key data presented at APASL and EASL 2025: At Week 48 (end of treatment [EOT]), 61% (11/18) of patients who previously responded to BRII-179 achieved HBsAg seroclearance, compared to 10% (1/10) of non-responders. Among responders, 91% (10/11) developed anti-HBs titers ≥100 IU/L. BRII-179-experienced participants achieved faster HBsAg loss, with 83% (10/12) achieving loss by Week 24, versus 55% (6/11) in BRII-179 naïve participants. The ENSURE study results demonstrate that prior treatment with BRII-179 and elebsiran can induce robust anti-HBs responses and enrich for patients more likely to achieve HBsAg loss. These data also suggest that most HBsAg loss may be achievable with a shorter PEG-IFNα treatment duration (24 weeks). The 24-week follow-up data of Cohort 4 of ENSURE study are expected in 2H 2025 and will be presented at a scientific conference. To further define BRII-179's role in HBV treatment and identify the optimal combination regimen for advancement into a registrational study, the Company is assessing BRII-179 in two additional Phase 2b trials: ENRICH Study: Evaluates the role of BRII-179 in priming HBV-specific immunity and/or identifying immuno-responsive patients with a higher likelihood of achieving functional cure. We continue to believe that BRII-179 may play a unique role as part of the curative regimens. ENHANCE Study:Evaluates a triple combination treatment regimen of BRII-179 and elebsiran plus PEG-IFNα to enhance the functional cure on insight from ENSURE Cohort 4, we amended the protocol to evaluate a simplified triple combination regimen aimed at shortening PEG-IFNα treatment duration to 24 studies have been fully enrolled. EOT data from ENRICH and ENHANCE are expected to be presented at a scientific conference in the first half of 2026. The Company has engaged with CDE of NMPA on potential Phase 3 study design and primary endpoints. The results from the ongoing ENRICH and ENHANCE studies will inform which final combination regimen will be taken forward to potential registrational studies. Additional Clinical Programs Brii Bio is actively seeking external partnerships to advance the development and commercialization of its therapeutic candidates for HIV and multidrug-resistant/extensively drug-resistant (MDR/XDR) infections. In July 2025, the Company announced the strategic out-licensing agreement with Joincare Group for the research, development, and commercialization of soralimixin (BRII-693) in Greater China region. This collaboration will leverage Joincare Group's strong capabilities in anti-infective therapeutics to accelerate the development and maximize the commercial potential of soralimixin (BRII-693). The Company will continue to seek non-dilutive funding or partnership opportunities for rights outside of Greater China. Outlook Looking ahead, Brii Bio remains committed to delivering innovative therapies for infectious diseases, with a continued focus on achieving a functional cure for HBV. With key data readouts from its HBV functional cure program expected in the first half of 2026, the Company is well-positioned to make informed decisions that will shape the next phase of its HBV functional cure clinical strategy. Following the appointment of its new CSO last year, Brii Bio has further expanded its internal discovery team and capabilities, complementing the continued advancement of its core HBV program. Brii Bio will continue to scale up its early discovery efforts to strengthen its innovation engine and reinforce its position at the forefront of biotech breakthroughs. Interim 2025 Financial Results The Company maintains a strong cash position to support its operations through 2028. Our bank deposits and cash and cash equivalents were RMB2,075.3 million as of June 30, 2025, representing a decrease of RMB338.1 million or 14.0% compared with RMB2,413.4 million as of December 31, 2024. The decrease was primarily due to payout of research and development activities and daily operations. Through pipeline prioritization, resource optimization, internalization of certain clinical development activities, and cost-saving measures of third-party contractors, we have effectively controlled our operational expenses. Research and development expenses were RMB117.0 million for the six months ended June 30, 2025, representing a decrease of RMB9.2 million or 7.3%, compared with RMB126.2 million for the six months ended June 30, 2024. The decrease reflected disciplined pipeline prioritization and organizational streamlining, while maintaining continued investment in core programs during the first half of 2025. Administrative expenses were RMB58.2million for the six months ended June 30, 2025, representing a decrease of RMB20.4 million or 26.0%, compared with RMB78.6 million for the six months ended June 30, 2024. The decrease was primarily attributable to the decrease in employee cost of RMB9.5 million and the decrease in facility-related costs and professional service fees of RMB8.4 million, which was primarily attributable to organizational optimization and effective cost control. Other income was RMB28.1 million for the six months ended June 30, 2025, representing a decrease of RMB42.8 million or 60.4%, compared with RMB70.9 million for the six months ended June 30, 2024. This was mainly due to the decrease in bank interest income of RMB21.6 million attributable to the declining interest rates on CNY and HKD time deposits, reallocation of short-term deposits to money market fund investments, and the decrease in income recognized from PRC government grants. Conference Call Information The Company will host two live conference calls. The English session will be held August 21 at 9:00 p.m. HKT (9:00 a.m. ET), For the registration link, please click here. Followed by a Chinese session on August 22 at 9:00 a.m. HKT (9:00 p.m. ET on August 21). For the registration link, please click here. All participants shall use the link provided above to complete the online registration process prior to the conference call. A replay of the conference call will be available after the call and can be accessed by visiting the Company's website at under the Investor Relations section. This press release contains references to third-party information. Such information is not deemed to be incorporated by reference in this press release. Brii Bio disclaims responsibility for such third-party information. About Brii Bio Brii Biosciences Limited ("Brii Bio," stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit Forward-Looking Statement The information communicated in this press release contains certain statements that are or may be forward-looking. These statements typically contain words such as "will," "expects," "believes," "plans" and "anticipates," and words of similar import. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company is unaware. These forward-looking statements are not a guarantee of future performance. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments. View original content to download multimedia: SOURCE Brii Biosciences Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data